Liver fibrosis is an urgent public health problem which is difficult to resolve. However, various drugs for the treatment of liver fibrosis in clinical practice have their own problems during use. In this study, we used phloridzin to treat hepatic fibrosis in the CCl4-induced C57/BL6N mouse model, which was extracted from lychee core, a traditional Chinese medicine. The therapeutic effect was evaluated by biochemical index detections and ultrasound detection. Furthermore, in order to determine the mechanism of phloridzin in the treatment of liver fibrosis, we performed high-throughput sequencing of mRNA and lncRNA in different groups of liver tissues. The results showed that compared with the model group, the phloridzin-treated groups revealed a significant decrease in collagen deposition and decreased levels of serum alanine aminotransferase, aspartate aminotransferase, laminin, and hyaluronic acid. GO and KEGG pathway enrichment analysis of the differential mRNAs was performed and revealed that phloridzin mainly affects cell ferroptosis. Gene co-expression analysis showed that the target genes of lncRNA were obvious in cell components such as focal adhesions, intercellular adhesion, and cell–substrate junctions and in metabolic pathways such as carbon metabolism. These results showed that phloridizin can effectively treat liver fibrosis, and the mechanism may involve ferroptosis, carbon metabolism, and related changes in biomechanics.
Idiopathic pulmonary fibrosis is a fatal interstitial disease characterized by fibroblast proliferation and differentiation and abnormal accumulation of extracellular matrix, with high mortality and an increasing annual incidence. Since few drugs are available for the treatment of pulmonary fibrosis, there is an urgent need for high-efficiency therapeutic drugs and treatment methods to reduce the mortality associated with pulmonary fibrosis. The interstitium, a highly efficient transportation system that pervades the body, plays an important role in the occurrence and development of disease, and can be used as a new route for disease diagnosis and treatment. In this study, we evaluated the administration of hydroxysafflor yellow A phytosomes via intervaginal space injection (ISI) as an anti-pulmonary fibrosis treatment. Our results show that this therapeutic strategy blocked the activation of p38 protein in the MAPK-p38 signaling pathway and inhibited the expression of Smad3 protein in the TGF-β/Smad signaling pathway, thereby reducing secretion of related inflammatory factors, deposition of collagen in the lungs of mice, and destruction of the alveolar structure. Use of ISI in the treatment of pulmonary fibrosis provides a potential novel therapeutic modality for the disease.
Ethnopharmacological relevance: Lycium barbarum L.(Solanaceae) has long been used to protect the liver and improve eyesight in traditional medicine. However, it remains unknown whether its glycopeptide (LbGp) can simultaneously ameliorate diabetic retinopathy (DR) via the hepatic-ophthalmic axis. Aim of the study: This study aims to investigate the therapeutic effect of LbGp on diabetic liver-eye comorbidity and explore its underlying mechanisms. Materials and methods: The retinal laminar structure and fundus vasculopathy of early DR mice were observed by optical coherence tomography (OCT) and fundus fluorescein angiography (FFA). The integrity of the blood retinal barrier (BRB) was evaluated by transmission electron microscopy and immunofluorescence. The pathological changes of liver tissue were observed by histological sections, and serum biochemical indexes were detected by kit. The potential mechanism was explored by multi omics analysis and western blotting.Results: Early DR in db/db mice was characterized by retinal thinning and mild edematous degeneration. LbGp intervention significantly reduced cellular edema and increased the thickness of the inner nuclear layer (INL) and photoreceptor outer segment (POS) layer to the retinal pigment epithelium (RPE) layer. LbGp restored the expression of tight junctions, Claudin-1, Occludin, and the endothelial cell marker CD31 in the BRB. Furthermore, LbGp ameliorated dyslipidemia, serum cholestasis, and hepatic injury in DR mice. Combined serum metabolomics and liver proteomics analysis revealed that LbGp primarily modulates pathways including fatty acid metabolism, unsaturated fatty acid biosynthesis, and ABC transporters. Mechanistic studies reveal that LbGp promotes cholesterol transport by upregulating LXR-α/ABCA1/ABCG1 expression, while simultaneously enhancing cholesterol conversion through increased CYP7A1/CYP8B1 and ABCG2 expression. This dual action facilitates the production of HDL, apoA-I, and pre-β-HDL while reducing LDL, FC, and 7KC deposition.Conclusion: This study shows that LbGp can simultaneously improve early DR and liver metabolic dysfunction in db/db mice. In terms of mechanism, it was found for the first time that LbGp activated the LXR-α/ABC transporter pathway, and confirmed that LXR-α mediated lipid metabolism was a potential therapeutic target for intervention of hepatic-ophthalmic axis in diabetic complications